|Page (1) of 1 - 04/16/18||email article||print page|
iSchemaView Names Don Listwin as CEO(April 16, 2018)
REDWOOD CITY, Calif. (PRWEB) April 16, 2018
iSchemaView, the leader in cerebrovascular imaging analysis, today announced that former Cisco and Openwave Systems executive, Don Listwin, has joined the company as Chief Executive Officer (CEO). Listwin comes to iSchemaView with over 30 years of technology management experience, helping dramatically grow both large and emerging brands.
“Don stands out as a highly respected leader with an incredible track record of success. He will ensure that iSchemaView capitalizes on its leadership position as the company that provides automated software solutions that aid in the diagnosis of cerebrovascular disease, and are used by many of the world's leading stroke centers as they work to identify and successfully treat more patients than ever before," said Gregory W. Albers MD, Stanford University Neurologist and cofounder of iSchemaView. “RAPID is the only imaging software solution used in the studies that selected patients for stroke treatment in the expanded window between six and twenty-four hours. Don will help us not just grow quickly, but also intelligently, as we meet the large demand for clinically proven imaging software in the US and around the world."
iSchemaView's RAPID platform assists physicians in the analysis of brain images using automated tools for CT, CT Perfusion and MR diffusion and perfusion. Under IRB approval, RAPID was recently used to select patients for two landmark stroke trials published in The New England Journal of Medicine, DAWN and DEFUSE 3, that successfully treated patients up to twenty-four hours after onset. RAPID was the exclusive imaging tool used to aid in patient selection in both studies. The results of the studies have changed the AHA stroke guidelines to include CT Perfusion and MR perfusion.
The prior treatment window for mechanical thrombectomy was up to six hours. Starting in 2018, select patients with salvageable brain tissue identified through advanced imaging are now eligible for treatment up to twenty-four hours after they were last seen well.
“Greg and his co-founder Doctor Roland Bammer, innovators in the treatment of stroke, had a mission to eliminate the long-term dogma that stroke was untreatable after three to six hours," said Don Listwin, CEO of iSchemaView. “With an intuitive but novel approach to brain imaging they are achieving their goal. And with a world of healthcare administrators and clinicians interested in taking advantage of new guidelines I look forward to helping iSchemaView achieve business success and more importantly to help physicians effectively diagnose and treat many more afflicted patients than previously thought possible."
Don Listwin spent a decade at Cisco Systems, where he served as executive vice president. During his tenure at Cisco, Don built several multi-billion-dollar lines of business, including the company's Service Provider line of business that underpins much of today's global Internet infrastructure. More recently, Listwin served as chief executive officer of both Sana Security and Openwave Systems.
In addition, Don founded and holds the role of chief executive officer of the Canary Foundation, a non-profit research organization focused on the early detection of cancer. He also serves as a director on the boards of AwareX, Calix, D-wave, POET Technologies, iSchemaView, Robin Systems and Teradici. Previously, he also served on the boards or was an advisor to JDS Uniphase, PLUMgrid, Redback Networks, E-TEK Dynamics, the Cellular Telecommunications & Internet Association (CTIA) and the Business Development Bank of Canada (BDC).
Listwin received a BSEE from the University of Saskatchewan, He is also a consulting professor in the School of Medicine at Stanford University
iSchemaView is the leader in cerebrovascular imaging analysis, delivering the proven software tools that healthcare professionals around the world use to successfully identify and treat more stroke patients than ever before. iSchemaView's RAPID is the most advanced brain imaging platform, and in clinical trials, under IRB, RAPID has been shown to aid in the selection of patients in early and late window stroke trials, including SWIFT PRIME, EXTEND IA, DAWN and DEFUSE 3. In addition to achieving the best clinical outcomes and largest treatment effects ever obtained, these landmark studies led to new American Heart Association and American Stroke Association guidelines, and have dramatically altered the management of acute stroke around the world. For more information, visit http://www.iRAPID.com
Read the full story at http://www.prweb.com/releases/2018/04/prweb15409723.htm.